William Trotter, MD
Ophthalmology · Ventura, CANPI 1447290515
Payments from drug & device makers
Across 137 payments — averaging $54.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Glaukos Corporation$2K
- AbbVie$843
- Aerie Pharmaceuticals, Inc.$408
- Bausch & Lomb, A Division Of Bausch Health US, LLC$275
- Regeneron Healthcare Solutions, Inc.$250
- plus $1K from 16 others
What the payments were for
- Travel & lodging$320%
- Food & beverage$7,36499%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 40 | $2,747 |
| Glaukos Corporation | 21 | $1,698 |
| AbbVie(2 entities) | 30 | $843 |
| Aerie Pharmaceuticals, Inc. | 5 | $408 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $275 |
| Regeneron Healthcare Solutions, Inc. | 2 | $250 |
| Bausch & Lomb Americas Inc. | 3 | $168 |
| Carl Zeiss Meditec USA, Inc. | 2 | $168 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $166 |
| Novartis | 6 | $118 |
| ANI Pharmaceuticals, Inc. | 1 | $116 |
| Amgen | 1 | $116 |
| Sun Pharmaceutical Industries Inc. | 4 | $99 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| Oyster Point Pharma, Inc. | 2 | $37 |
| Dompe US, Inc. | 1 | $34 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Biotissue Holdings Inc. | 1 | $25 |
| Harrow Eye, LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Johnson & Johnson Vision Care, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$538
- iDoseTR$463
- Rhopressa$375
- Clareon PanOptix Pro$272
- enVista MX60 IOL$256
- iStent inject W$235
- iStent Trabecular Micro-Bypass System Model iS3$215
- Hydrus Microstent$164
- QUATERA 700$153
- IOLMaster 700$153
- NGENUITY$149
- LenSx$143
- AcrySof IQ PanOptix UV IOL$138
- AcrySof IQ PanOptix$135
- Constellation$129
- enVista Aspire IOL$128
- iStent inject Trabecular Micro-Bypass Stent System$127
- XEN$125
- EYLEA$125
- EYLEA HD$125
How this compares
$7,442 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 474 | $270,480 |
| RestasisCyclosporine | 90 | $125,175 |
| RhopressaNetarsudil Mesylate | 117 | $61,333 |
| RocklatanNetarsudil Mesylat/Latanoprost | 68 | $55,834 |
| XiidraLifitegrast | 39 | $39,815 |
| Brimonidine Tartrate | 376 | $36,157 |
| Cyclosporine | 51 | $34,734 |
| Alphagan PBrimonidine Tartrate | 111 | $34,568 |
| CombiganBrimonidine Tartrate/Timolol | 78 | $30,897 |
| Travoprost | 152 | $21,733 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 96 | $19,542 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 47 | $18,609 |
| VyzultaLatanoprostene Bunod | 21 | $12,369 |
| Latanoprost | 1,087 | $10,508 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 764 | $10,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $843 | $461,119753 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $408 | $117,167185 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $168 | $52,18460 claims |
| AlconSimbrinza | $2,747 | $18,60947 claims |
| NovartisTravatan Z | $118 | $6,33917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Ventura
- Aaron NagielVentura$1.1M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.